- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Adjunctive AI Software for Cardiac Ultrasound Gets FDA Nod
Employing an artificial intelligence (AI)-powered scoring system, LVivo IQS reportedly provides real-time assessment of the quality of cardiac ultrasound images.
The Food and Drug Administration (FDA) has granted 510(k) clearance to LVivo IQS (DiA Imaging Analysis), which facilities heart assessment through an artificial intelligence (AI)-enabled quality scoring system for cardiac ultrasound images.
As clinicians perform ultrasound scanning of the left ventricle of the heart, the LVivo IQS (Image Quality Score) generates colors and numerical scoring to provide real-time assessment of image quality, according to DiA Imaging Analysis.
In a clinical study assessing the AI-powered image scoring system, DiA Imaging Analysis found that 91 percent of point-of-care cardiac ultrasound images obtained by residents using the LVivo IQS software were deemed to be clinically interpretable images by cardiologists.
Lior Fuchs, M.D., the principal investigator of the study, said LVivo IQS is a significant advance in the cardiac ultrasound arena.
“For precise heart diagnosis and treatment, high-quality cardiac ultrasound imaging is necessary in both point-of-care and other settings,” noted Dr. Fuchs, a senior intensive care physician affiliated with the Soroka Medical Center in Israel. “LVivo IQS AI software will assist us in obtaining faster and clearer images to aid our real-time clinical decision-making process.”
(Editor’s note: For related content, see “Clarius Mobile Health Gets FDA Nod for AI Ultrasound Musculoskeletal Imaging Model” and “Pie Medical Imaging Launches AI-Powered Echocardiography Platform.”)
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
